The central government has now swung into action after the name of the Indian syrup company was linked to the death of 66 children in The Gambia. The Center has constituted a committee to probe the issue.
The committee has been constituted under the chairmanship of Dr. YK Gupta, Vice Chairman of the Standing National Committee on Medicine. After the investigation of the matter, the expert committee will present the details. At present, the test report of the cough syrup sample taken for testing is yet to come.
According to sources, until the investigation report comes, the production of the company will be closed. When the ministry was asked that if 4 samples of the company fail, then how can the entire batch be blamed?
On this it was replied that joint inspection is being done. Now all eyes are on the lab report.
On 1st, 3rd, 6th and 11th October the place where this syrup was being produced was inspected. During this, samples of medicines of that batch were collected and sent to Chandigarh Lab.
The Haryana government has banned the production of Maiden Pharma, a Haryana-based company that makes cough syrup. The Haryana State Drug Authority had found many irregularities in the functioning of Maiden Pharma Company located in Sonipat. After this the Haryana government had taken this step.
Earlier, the World Health Organization had declared 4 cough syrups of Indian companies as fatal. After this the team of Health Department reached Maiden Pharmaceutical Company in Sonepat. During the investigation, the officials have found 12 irregularities in the company based in Sonipat.
It is being told that the quality testing of the raw material used in the manufacture of syrup was not being done. The Haryana State Drug Authority has asked the company to respond to the show cause notice within 7 days. It has been asked why his license should not be revoked.
Also Read – International Indigenous day 2022: Everything You Need To Know
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
